Fate Therapeutics (FATE) Equity Average (2013 - 2026)

Fate Therapeutics has reported Equity Average for 14 years, with the latest figure at $193.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 36.28% year-over-year to $193.4 million; the trailing twelve-month figure through Mar 2026 stood at $193.4 million (down 36.28% YoY), and the FY2025 full-year result was $263.0 million, down 23.46% from the prior year.
• Equity Average for Q1 2026 stood at $193.4 million, down from $220.6 million in the prior quarter.
• The five-year high for Equity Average was $656.1 million in Q1 2022, with the low at $193.4 million in Q1 2026.
• Historically, Equity Average has averaged $401.6 million across 5 years, with a median of $397.3 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average gained 11.72% — and 2026, when it plunged 36.28%.
• Fate Therapeutics' Equity Average stood at $501.0 million in 2022, then declined by 23.03% to $385.6 million in 2023, then fell by 11.69% to $340.5 million in 2024, then sank by 35.21% to $220.6 million in 2025, then fell by 12.32% to $193.4 million in 2026.
• The last three Equity Average figures came in at $193.4 million (Q1 2026), $220.6 million (Q4 2025), and $247.7 million (Q3 2025), per Business Quant data.